Celecoxib associated esophagitis: Review of gastrointestinal side effects from COX-2 inhibitors

Journal of Clinical Gastroenterology

Volumn 37, Issue 1, 2003, Pages 61-63

  Mantry, Parvez S ^a   Shah, Ashok ^a   Sundaram, Uma ^a  

^a Box 646 ^*

Author keywords

Celecoxib; COX 2 inhibitors; Esophagitis

Indexed keywords

CELECOXIB; ENALAPRIL; ESOMEPRAZOLE; RABEPRAZOLE; ROFECOXIB;

ACHLORHYDRIA; AGED; ARTICLE; CASE REPORT; ENZYME INHIBITION; ESOPHAGITIS; ESOPHAGUS BIOPSY; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MALE; PAIN; PRIORITY JOURNAL; STOMACH CONTENT; STOMACH MUCOSA; TRIGEMINUS NEURALGIA; ULCER; UPPER GASTROINTESTINAL TRACT;

AGED; AGED, 80 AND OVER; CYCLOOXYGENASE INHIBITORS; ESOPHAGEAL STENOSIS; ESOPHAGITIS; HUMANS; MALE; PYRAZOLES; SULFONAMIDES; TRIGEMINAL NEURALGIA;

EID: 0038613635     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200307000-00015     Document Type: Article

References (12)

1. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl. 1991;28:6-10.
2. Halter F, Tarnawski A S, Schmassmann A, et al. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: Controversial issues and perspectives review. Gut. 2001;49:443-445.
3. Linder JD, Monkemuller KE, Davis JV, et al. Cyclooxygenase-2 inhibitor Celecoxib: A possible cause of gastropathy and hypoprothrombinemia. Southern Medical Journal. September. 2000;93:930-932.
4. Mohammed S, Croom DW. Gastropathy due to Celecoxib, a cyclooxygenase-2 inhibitor, letter. New Engl J Med. 2005;199:340.
5. Zimmerman KC, Sarbia M, Schror K, et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol. 1998;54:536-540.
6. Lipsky P, Brooks P, Crofford L, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch of Internal Med. 2000;160:913-920.
7. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and it's inhibition by the specific antagonist delays in mice. Gastroenterology 1997;112:387-397.
8. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of Rofecoxib, a cyclooxygenase 2-specific inhibitor with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology. 1999;117:776-783.
9. Hubbard R, Geis GS, Yu S, et al. Efficacy, tolerability, and safety of Celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum. 1998;41:S196.
10. Simon LS, Lanza FL, Lipsky PE, et al. Anti-inflammatory and upper gastrointestinal effects of Celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-1928.
11. Langman M, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of Rofecoxib compared with NSAIDs. JAMA. 1999;282:1929-1933.
12. Mark Feldman, Alexander McMahon. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Of Internal Med. 2000;132:134-143.